Newcastle Confidence in Concept 2018

Lead Research Organisation: Newcastle University
Department Name: UNLISTED

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

The Confidence in Concept (CIC) scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions to flexibly support a portfolio of early stage translational research projects. CIC is designed to accelerate the transition from discovery research to viable translational projects by supporting preliminary studies to establish proof-of-concept so that the approach will then become competitive for more substantial translational funding

People

ORCID iD
 
Description GlycoScore: A non-invasive test for prostate cancer
Amount £49,655 (GBP)
Organisation United Kingdom Research and Innovation 
Department Northern Accelerator
Sector Charity/Non Profit
Country United Kingdom
Start 09/2020 
 
Description GlycoScore: Superior prostate cancer diagnosis using a simple blood test
Amount £150,000 (GBP)
Funding ID NIHR202523 
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 03/2021 
End 02/2022
 
Description GlycoScore: a new non-invasive blood test for prostate cancer
Amount £50,000 (GBP)
Organisation Innovate UK 
Sector Public
Country United Kingdom
Start 01/2020 
 
Description GlycoScore: a novel blood test for prostate cancer
Amount £150,000 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 03/2021 
 
Description GlycoScore: a superior blood test to diagnose prostate cancer
Amount £209,981 (GBP)
Organisation Innovate UK 
Sector Public
Country United Kingdom
Start 03/2021 
 
Description Newcastle Confidence in Concept - Care Pathway analysis and further validation for GlycoScore: a novel blood test for prostate cancer
Amount £66,149 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 02/2021 
End 03/2022
 
Title Prostate cancer biomarkers 
Description A kit for diagnosing prostate cancer or determining the risk of developing prostate cancer in a subject, comprising (i) a detectably labelled agent that specifically binds to ST6GAL1 protein; and (ii) one or more of: (a) a detectably labelled agent that specifically binds GALNT7 protein; and (b) a detectably labelled protein that specifically binds to FUT8. An assay device for diagnosing prostate cancer or determining the risk of developing prostate cancer in a subject is also disclosed; the device comprising a surface with at least two detectably labelled agents located thereon, wherein the at least two detectably labelled agents are as define above. The kit or assay device may comprise a plurality of distinct detectably labelled agents that specifically independently bind to GALNT7, ST6GAL1 and GCNT1; or ST6GAL1, GCNT1 and FUT8. The kit or assay may further comprise a detectably labelled agent which binds to Prostate-Specific Antigen (PSA) protein. The kit may further comprise one or more control samples or references; and/or one or more reagents for detecting the detectably labelled agent(s). The surface may be a continuous surface, particularly a surface comprising a lateral flow surface, dot plot surface, dipstick surface or surface suitable for plasmon resonance. 
IP Reference GB2595425 
Protection Patent granted
Year Protection Granted 2021
Licensed No
Impact The present invention provides novel biomarkers for prostate cancer. Methods for diagnosing prostate cancer or the risk of developing prostate cancer, or for monitoring prostate cancer progression (including prostate cancer relapse) and methods for treatment of prostate cancer are also provided. The invention also provides methods for determining the therapeutic effect of appropriate treatment regimens for prostate cancer or determining a subject's compliance or adherence with a prescribed treat
 
Company Name GLYCOSCOREDX LIMITED 
Description GlycoScoreDx Ltd is a new spin-out company originating from Newcastle University. The company was established in 2021 after receiving seed funding from Innovate UK (£210,000, plus matched private investment funding) to support establishment of the business and the commercial development of the GlycoScore test. GlycoScoreDx's vision is to provide superior cancer diagnostics, using simple to use detection methods that require no capital investment for the customer. The business is founded on more than a decade of research in the area of glycosylation and cancer, undertaken by Dr Jennifer Munkley and her team, which led to the discovery of the GlycoScore test. The company aims to provide innovative new diagnostics that are based on understanding the fundamental pathology of disease rather than variable expression of different markers. GlycoScore can be used in different ways for diagnosing prostate cancer, including initial diagnosis, prognosis and active surveillance. 
Year Established 2020 
Impact The care pathway analysis and health economic modelling proposed in this study will provide invaluable information for the design of the clinical utility study and future clinical adoption. In addition to GlycoScore, the company has an innovation team that are validating a new diagnostic for pancreatic cancer, which will be the second product in our portfolio.
 
Description Presentation to International Sarcopenia Translational Research Conference June 2021 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Communications to the International Sarcopenia Translational Research Conference 10-11 June 2021 (Virtual) - Study in Novel Neuro-Muscular Imaging Biomarkers for Motor Outcome in Stroke (Sinonims).
Year(s) Of Engagement Activity 2021
URL https://www.jfsf.eu/Article.php?AID=v06i03_163